Literature DB >> 29611528

Medication overuse in oncology: current trends and future implications for patients and society.

Stephen M Schleicher1, Peter B Bach2, Konstantina Matsoukas3, Deborah Korenstein1.   

Abstract

The high cost of cancer care worldwide is largely attributable to rising drugs prices. Despite their high costs and potential toxic effects, anticancer treatments could be subject to overuse, which is defined as the provision of medical services that are more likely to harm than to benefit a patient. We found 30 studies documenting medication overuse in cancer, which included 16 examples of supportive medication overuse and 17 examples of antineoplastic medication overuse in oncology. Few specific agents have been assessed, and no studies investigated overuse of the most toxic or expensive medications currently used in cancer treatment. Although financial, psychological, or physical harms of medication overuse in cancer could be substantial, there is little published evidence addressing these harms, so their magnitude is unclear. Further research is needed to better quantify medication overuse, understand its implications, and help protect patients and the health-care system from overuse.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29611528      PMCID: PMC6207078          DOI: 10.1016/S1470-2045(18)30099-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  89 in total

Review 1.  Global Health Equity: Cancer Care Outcome Disparities in High-, Middle-, and Low-Income Countries.

Authors:  Jonas A de Souza; Bijou Hunt; Fredrick Chite Asirwa; Clement Adebamowo; Gilberto Lopes
Journal:  J Clin Oncol       Date:  2015-11-17       Impact factor: 44.544

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 3.  Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis.

Authors:  J Herrstedt; F Roila
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

4.  American Society of Clinical Oncology 2013 top five list in oncology.

Authors:  Lowell E Schnipper; Gary H Lyman; Douglas W Blayney; J Russell Hoverman; Derek Raghavan; Dana S Wollins; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2013-10-29       Impact factor: 44.544

5.  Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Authors:  Arnold L Potosky; Jennifer L Malin; Benjamin Kim; Elizabeth A Chrischilles; Solomon B Makgoeng; Nadia Howlader; Jane C Weeks
Journal:  J Natl Cancer Inst       Date:  2011-06-13       Impact factor: 13.506

6.  Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Authors:  Omar Abdel-Rahman; Mona Fouad
Journal:  Ther Adv Respir Dis       Date:  2016-03-04       Impact factor: 4.031

Review 7.  Bone health in men receiving androgen deprivation therapy for prostate cancer.

Authors:  James A Eastham
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

Review 8.  Colony-stimulating factors for febrile neutropenia during cancer therapy.

Authors:  Charles L Bennett; Benjamin Djulbegovic; LeAnn B Norris; James O Armitage
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

Review 9.  Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Authors:  Geralyn E Waters; Patricia Corrigan; Mandy Gatesman; Thomas J Smith
Journal:  J Oncol Pract       Date:  2012-11-06       Impact factor: 3.840

10.  Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.

Authors:  Ayako Okuyama; Fumiaki Nakamura; Takahiro Higashi
Journal:  JAMA Oncol       Date:  2017-03-01       Impact factor: 31.777

View more
  8 in total

Review 1.  Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms.

Authors:  Arjun Gupta; Leonce Nshuti; Udhayvir S Grewal; Ramy Sedhom; Devon K Check; Helen M Parsons; Anne H Blaes; Beth A Virnig; Maryam B Lustberg; Ishwaria M Subbiah; Ryan D Nipp; Sydney M Dy; Stacie B Dusetzina
Journal:  JCO Oncol Pract       Date:  2021-09-24

2.  Factors affecting the implementation of guideline-based prophylactic antiemetic therapy for chemotherapy-induced nausea and vomiting in Japan: a protocol for a hospital-based qualitative study.

Authors:  Akiko Yaguchi-Saito; Yuki Kaji; Ayumu Matsuoka; Ayako Okuyama; Maiko Fujimori; Junko Saito; Miyuki Odawara; Aki Otsuki; Yosuke Uchitomi; Sadamoto Zenda; Taichi Shimazu
Journal:  BMJ Open       Date:  2022-06-06       Impact factor: 3.006

3.  Cutaneous melanoma: cost of illness under Brazilian health system perspectives.

Authors:  Cassia Rita Pereira da Veiga; Claudimar Pereira da Veiga; Alceu Souza; Alberto Julius Alves Wainstein; Andreia Cristina de Melo; Ana Paula Drummond-Lage
Journal:  BMC Health Serv Res       Date:  2021-03-29       Impact factor: 2.655

Review 4.  Financial toxicity of cancer care in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Andrew Donkor; Vivian Della Atuwo-Ampoh; Frederick Yakanu; Eric Torgbenu; Edward Kwabena Ameyaw; Doris Kitson-Mills; Verna Vanderpuye; Kofi Adesi Kyei; Samuel Anim-Sampong; Omar Khader; Jamal Khader
Journal:  Support Care Cancer       Date:  2022-04-25       Impact factor: 3.359

5.  What Promotes Medical Overuse: Perspective on Evolutionary Game between Administration and Medical Institutions.

Authors:  Chenxi Xu; Li Luo; Siyu Zeng; Xiaozhou He; Jialing Li; Guiju Zhu
Journal:  Comput Math Methods Med       Date:  2022-09-14       Impact factor: 2.809

6.  The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: A difference-in-differences analysis in a large tertiary hospital in China.

Authors:  Yuan-Jin Zhang; Yan Ren; Quan Zheng; Jing Tan; Ming-Hong Yao; Yun-Xiang Huang; Xia Zhang; Kang Zou; Shao-Yang Zhao; Xin Sun
Journal:  Front Public Health       Date:  2022-08-12

7.  Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews.

Authors:  M Santero; J Pérez-Bracchiglione; R Acosta-Dighero; A G Meade; A Antequera; A Auladell-Rispau; M J Quintana; C Requeijo; G Rodríguez-Grijalva; K Salas-Gama; R Dorantes-Romandia; J Salazar; I Solà; G Urrútia; X Bonfill Cosp
Journal:  BMC Cancer       Date:  2021-06-16       Impact factor: 4.430

8.  De-implementing low-value care in cancer care delivery: a systematic review.

Authors:  Amir Alishahi Tabriz; Kea Turner; Alecia Clary; Young-Rock Hong; Oliver T Nguyen; Grace Wei; Rebecca B Carlson; Sarah A Birken
Journal:  Implement Sci       Date:  2022-03-12       Impact factor: 7.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.